Retina

Inflammation is par for the course in ocular gene therapy; preventing it should be the goal because once it develops, treatment can be difficult.

Combining ECP with vitrectomy can reduce medication use following the procedure and in some cases avoid the need for further surgery.

An end-of-week review of what happened in ophthalmology from 29 October to 3 November 2022.

A global survey of retinal experts assessed their perceptions of evolving clinical practice in the Covid-19 era, focusing on digital teleophthalmology, home monitoring and decentralised patient care.

A small study demonstrates that high-resolution imaging with adaptive optics may be a useful method of assessing integrity of the cone mosaic following macular hole repair.

Investigators evaluated VA outcomes after cataract surgery and the factors associated with good visual outcomes in a population of patients with type 2 diabetes.

The COVID-19 pandemic has led to greater comfort with robotic telepresence in eye screenings.

Investigators report that a gel-forming sustained-delivery eye drop containing sunitinib can provide increased intraocular absorption of the drug while protecting retinal cells.

Study images showed that large drusen compressed the inner macula and distorted the tissue architecture, and geographic atrophy resulted in posterior prolapse of the inner retinal layers.

AI and teleophthalmology both show very high level of agreement with in-person evaluations, although further studies are needed to reduce the number of ungradable images.

Central tenotomy and central plication are just two options that can correct very small deviations previously not amenable to surgical treatment.

The goal of World Sight Day, according to IAPB, is “to shine a light on blindness and vision impairment as a major, but solvable, public health issue."

A combination of posters, podium presentations and instructional courses provided invaluable revelations to the ophthalmic community.

Companies are exploring light-sensitive proteins method in patients with advanced disease.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all terciles.

Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability and safety of faricimab in patients with neovascular AMD.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Data highlights need for educational materials and training resources in DMO and DR.

12-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.

Symptoms of acute optic neuritis resulting from the disease can resolve in treated rapidly.

Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.

According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.